Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
1 finding from 1 review
- HR 0.75 [0.54, 1.04]1 study · 339 participantsLow